{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004927","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.414673+00:00","generated_at":"2026-06-06T09:13:37.781718+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shuttle Pharma acquires PSMA-Boron theranostic asset; engages new IR firm","bullets":["Upfront $10k each and milestone payments up to $40k each to inventors; 3% royalty on net revenues.","PSMA-Boron is a theranostic agent for diagnosis, staging, and therapy of prostate cancer.","Company engaged John Columbia Inc. to supplement existing IR firm Lytham Partners.","Asset purchase agreement executed Jan 30, 2024; inventors assigned all rights to company."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004927","json":"https://secwatch.observer/filing/0001493152-24-004927.json","markdown":"https://secwatch.observer/filing/0001493152-24-004927.md","text":"https://secwatch.observer/filing/0001493152-24-004927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/0001493152-24-004927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:13:37.781718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5d1c750a323fe37da2f33e767f20de6c5ed2463","claim":"Shuttle Pharmaceuticals Holdings, Inc. entered into Asset Purchase Agreement with Alan Kozikowski and Werner Tueckmantel valued at Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research (effective 2024-01-30).","evidence_excerpt":"On January 30, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) and an Assignment of Invention Agreement (the “Assignment”) with Alan Kozikowksi and Werner Tueckmantel (together, the “Inventors”) pursuant to which the Inventors assigned all of their rights, title and interest in the invention entitled “PSMA-Boron” (the “Invention”) to the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224004927/0001493152-24-004927-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Alan Kozikowski and Werner Tueckmantel"},{"label":"Value","value":"Payment of $10,000 each upon signing; additional payments of $10,000 each upon receipt of a research"},{"label":"Effective","value":"2024-01-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}